Acadia Pharmaceuticals' 15min chart shows RSI oversold, KDJ golden cross.
ByAinvest
Thursday, Oct 16, 2025 2:47 pm ET1min read
ACAD--
The stock price of Acadia Pharmaceuticals experienced a notable decline following the announcement. On September 24, 2025, the stock fell by $2.34 per share, or 9.92%, closing at $21.26 per share, the report noted. This significant drop in stock price has raised concerns among investors.
Adding to the uncertainty, Pomerantz LLP has initiated an investigation into potential securities fraud or unlawful business practices on behalf of Acadia's investors. The law firm is advising investors to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, for more information.
Further analysis of Acadia's stock price using technical indicators has shown that the 15-minute chart triggered an RSI Oversold signal and a KDJ Golden Cross at 10/16/2025 14:45. This indicates a potential shift in the stock's momentum, suggesting a possible upward trajectory despite the recent decline.
Investors and financial professionals should closely monitor the developments in the investigation and the company's financial performance. As the stock price volatility continues, it is crucial to consider both the fundamental and technical aspects of the investment.
The 15-minute chart for Acadia Pharmaceuticals has triggered an RSI Oversold signal, coupled with a KDJ Golden Cross at 10/16/2025 14:45. This indicates that the stock price has experienced a significant decline, potentially exceeding its fundamental support levels. However, the momentum of the stock price is now shifting in favor of an upward trajectory, suggesting that there is potential for further growth.
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) has been facing significant challenges following the release of its Phase 3 COMPASS PWS trial results on September 24, 2025. The trial evaluated the efficacy and safety of intranasal carbetocin (ACP-101) in patients with hyperphagia in Prader-Willi syndrome (PWS). The drug failed to demonstrate statistically significant improvements over placebo, leading to a halt in further investigations, according to a Marketscreener report.The stock price of Acadia Pharmaceuticals experienced a notable decline following the announcement. On September 24, 2025, the stock fell by $2.34 per share, or 9.92%, closing at $21.26 per share, the report noted. This significant drop in stock price has raised concerns among investors.
Adding to the uncertainty, Pomerantz LLP has initiated an investigation into potential securities fraud or unlawful business practices on behalf of Acadia's investors. The law firm is advising investors to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, for more information.
Further analysis of Acadia's stock price using technical indicators has shown that the 15-minute chart triggered an RSI Oversold signal and a KDJ Golden Cross at 10/16/2025 14:45. This indicates a potential shift in the stock's momentum, suggesting a possible upward trajectory despite the recent decline.
Investors and financial professionals should closely monitor the developments in the investigation and the company's financial performance. As the stock price volatility continues, it is crucial to consider both the fundamental and technical aspects of the investment.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet